受强制性开放获取政策约束的文章 - Walter Hanel了解详情
无法在其他位置公开访问的文章：1 篇
Danqing Kong1, 2, Nana Ping1, 2, Xin Gao3, Rui Zou1, Peng Wang1, 2, Depei Wu1, 2, Zhengming Jin1, 2 and Changju Qu1, 2
N Epperla, W Hanel, M Iqbal, C Qu, D Wu, Z Jin
强制性开放获取政策： 国家自然科学基金委员会
可在其他位置公开访问的文章：18 篇
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
W Hanel, N Marchenko, S Xu, S Xiaofeng Yu, W Weng, U Moll
Cell Death & Differentiation 20 (7), 898-909, 2013
强制性开放获取政策： US National Institutes of Health
Links between mutant p53 and genomic instability
W Hanel, UM Moll
Journal of cellular biochemistry 113 (2), 433-439, 2012
强制性开放获取政策： US National Institutes of Health
Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding
ND Marchenko, W Hanel, D Li, K Becker, N Reich, UM Moll
Cell Death & Differentiation 17 (2), 255-267, 2010
强制性开放获取政策： US National Institutes of Health
SEF/IL-17R (SEFIR) is not enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction
RM Onishi, SJ Park, W Hanel, AW Ho, A Maitra, SL Gaffen
Journal of Biological Chemistry 285 (43), 32751-32759, 2010
强制性开放获取政策： US National Institutes of Health
BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis
V Bharti, R Watkins, A Kumar, RL Shattuck-Brandt, A Mossing, A Mittra, ...
Cell reports 41 (12), 2022
强制性开放获取政策： US Department of Defense, US National Institutes of Health, US Department of …
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
C Murga-Zamalloa, A Polk, W Hanel, P Chowdhury, N Brown, AC Hristov, ...
Oncotarget 8 (70), 114474, 2017
强制性开放获取政策： US National Institutes of Health, V Foundation, USA
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
SL Sloan, F Brown, M Long, C Weigel, S Koirala, JH Chung, B Pray, ...
Blood 142 (10), 887-902, 2023
强制性开放获取政策： US National Institutes of Health
Transducin b-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma
Y Youssef, V Karkhanis, WK Chan, F Jeney, A Canella, X Zhang, S Sloan, ...
Haematologica 106 (11), 2927, 2020
强制性开放获取政策： US National Institutes of Health
Outcomes of patients with limited‐stage plasmablastic lymphoma: a multi‐institutional retrospective study
BT Hess, A Giri, Y Park, KK Patel, BK Link, GS Nowakowski, SM Maliske, ...
American journal of hematology 98 (2), 300-308, 2023
强制性开放获取政策： US National Institutes of Health
Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis
CR D’angelo, W Hanel, Y Chen, M Yu, D Yang, L Guo, R Karmali, ...
Hematological oncology 39 (4), 473-482, 2021
强制性开放获取政策： US National Institutes of Health
A phase 2 trial of ibrutinib and nivolumab in patients with relapsed or refractory classical Hodgkin’s lymphoma
W Hanel, P Shindiapina, DA Bond, Y Sawalha, N Epperla, T Voorhees, ...
Cancers 15 (5), 1437, 2023
强制性开放获取政策： US National Institutes of Health
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
W Hanel, P Lata, Y Youssef, H Tran, L Tsyba, L Sehgal, BW Blaser, ...
Experimental Hematology & Oncology 11 (1), 40, 2022
强制性开放获取政策： US National Institutes of Health, American Brain Tumor Association
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
A Sircar, S Singh, ZY Xu-Monette, KM Coyle, LK Hilton, E Chavdoula, ...
Leukemia 37 (10), 2094-2106, 2023
强制性开放获取政策： US National Institutes of Health, Canadian Institutes of Health Research …
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
WK Chan, J Williams, K Sorathia, B Pray, K Abusaleh, Z Bian, A Sharma, ...
Experimental Hematology & Oncology 12 (1), 79, 2023
强制性开放获取政策： US National Institutes of Health
Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
Z Braunstein, E McLaughlin, M Ruiz, L Wei, N Bumma, D Benson, ...
Frontiers in oncology 12, 858426, 2022
强制性开放获取政策： US National Institutes of Health, American Heart Association, Robert Wood …
Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma
BT Hess, A Giri, Y Park, KK Patel, BK Link, GS Nowakowski, SM Maliske, ...
Blood 136, 15-16, 2020
强制性开放获取政策： US National Institutes of Health
Expansion of the hematopoietic stem cell compartment is necessary but not sufficient for gain-of-function mutant p53 R248Q to accelerate lymphomagenesis
AR Yallowitz, W Hanel, UM Moll
Cell Death & Differentiation 22 (8), 1397-1397, 2015
强制性开放获取政策： US National Institutes of Health
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
N Epperla, LJ Costa, JL Vaughn, W Hanel, S Raya, AF Cashen, ...
Blood 134, 1554, 2019
强制性开放获取政策： Lymphoma Research Foundation, USA
出版信息和资助信息由计算机程序自动确定